![""](/sites/default/files/2024-04/UofT93566_2022-07-18-Daniel-Drucker-8_Polina-Teif-crop.jpg)
Daniel Drucker (photo by Polina Teif)
Daniel Drucker among聽Time聽magazine鈥檚 100 most influential people
Published: April 17, 2024
Endocrinologist Daniel Drucker is part of a team of researchers recognized by Time magazine for their roles in advancing next-generation treatments for diabetes and weight loss.
Drucker, a senior investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, and a in the department of medicine at the 重口味SM's Temerty Faculty of Medicine, shares a spot on with Joel Habener of Harvard University and Svetlana Mojsov of Rockefeller University.
The scientists were honoured for their contributions to the development of a new class of drugs, including Ozempic and Wegovy, based on their discoveries about gut hormones known as glucagon-like peptides.
These medications, known as glucagon-like peptide-1 (GLP-1) receptor agonists, help manage blood sugar levels by boosting insulin production and reducing the liver鈥檚 release of sugar.
鈥淒rucker鈥檚 experiments pinpointed the specific parts of GLP-1 responsible for affecting insulin levels,鈥 the magazine said. 鈥淣ow GLP-1-based medications are approved in the U.S. to treat diabetes and obesity, and to reduce the risk of heart disease.鈥
Drucker, who has been recognized with a Gairdner International Award and Wolf Prize for his work, is currently exploring other potential health benefits, including reducing inflammation in chronic metabolic diseases.